Source comparison
Dosing Protocols: Weekly vs Twice-Weekly Administration
The standard CJC-1295 dosage protocol is 1000–2000 mcg administered subcutaneously once weekly, timed to coincide with the body's natural nocturnal GH pulse during deep sleep (typically 10 PM–2 AM). This timing leverages endogenous pulsatility. CJC-1295 amplif
This comparison does not assign a generated winner or score.
- The standard CJC-1295 dosage protocol is 1000–2000 mcg administered subcutaneously once weekly, timed to coincide with the body's natural nocturnal GH pulse during deep sleep (typically 10 PM–2 AM). This timing leverages endogenous pulsatility. CJC-1295 amplifies existing pulses rather than creating new ones, so aligning administration with the largest naturally occurring GH surge maximizes peak amplitude. Injecting in the morning produces measurable GH elevation but misses the deep-sleep pulse window, which accounts for 60–70% of daily GH secretion in healthy adults.
- Twice-weekly protocols (1000 mcg every 3–4 days) are used in research settings to maintain more consistent plasma levels and reduce the peak-to-trough variation seen with single weekly doses. This approach minimizes the IGF-1 spike that occurs 7–10 days post-injection and distributes receptor occupancy more evenly across the week. The tradeoff: twice-weekly dosing doubles injection frequency without necessarily doubling GH output. Receptor saturation limits additive effects. Clinical data from trials using CJC-1295 in GH-deficient populations showed no significant difference in mean 24-hour GH area-under-curve between 2000 mcg weekly and 1000 mcg twice weekly, suggesting the total weekly dose matters more than split frequency once therapeutic levels are achieved.
- Our experience working with peptide synthesis labs indicates most users achieve optimal results with 1500 mcg once weekly for 8–12 weeks, followed by a 4-week washout to restore pituitary sensitivity. Doses above 2000 mcg weekly consistently produce higher IGF-1 readings (mean increases of 80–120 ng/mL above baseline) but do not produce proportionally greater lean mass accrual or fat oxidation. The receptor binding curve flattens, and additional ligand availability creates no further downstream signaling.